Lack of effect of different pain-related manipulations on opioid self-administration, reinstatement of opioid seeking, and opioid choice in rats.
Analgesics, Opioid
/ administration & dosage
Animals
Choice Behavior
/ drug effects
Conditioning, Operant
/ drug effects
Drug-Seeking Behavior
/ drug effects
Extinction, Psychological
/ drug effects
Female
Fentanyl
/ pharmacology
Male
Opioid-Related Disorders
/ psychology
Pain
/ drug therapy
Pain Measurement
/ methods
Rats
Reinforcement, Psychology
Self Administration
/ methods
Extinction
Opioid choice
Opioid self-administration
Pain
Reinstatement
Relapse
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
12
02
2021
accepted:
01
03
2021
pubmed:
26
3
2021
medline:
6
7
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
Pain-related factors increase the risk for opioid addiction, and pain may function as a negative reinforcer to increase opioid taking and seeking. However, experimental pain-related manipulations generally do not increase opioid self-administration in rodents. This discrepancy may reflect insufficient learning of pain-relief contingencies or confounding effects of pain-related behavioral impairments. Here, we determined if pairing noxious stimuli with opioid self-administration would promote pain-related reinstatement of opioid seeking or increase opioid choice over food. In Experiment 1, rats self-administered fentanyl in the presence or absence of repeated intraplantar capsaicin injections in distinct contexts to model context-specific exposure to cutaneous nociception. After capsaicin-free extinction in both contexts, we tested if capsaicin would reinstate fentanyl seeking. In Experiment 2, rats self-administered heroin after intraperitoneal (i.p.) lactic acid injections to model acute visceral inflammatory pain. After lactic acid-free extinction, we tested if lactic acid would reinstate heroin seeking. In Experiment 3, we tested if repeated i.p. lactic acid or intraplantar Complete Freund's Adjuvant (CFA; to model sustained inflammatory pain) would increase fentanyl choice over food. In Experiments 1-2, neither capsaicin nor lactic acid reinstated opioid seeking after extinction, and lactic acid did not increase heroin-induced reinstatement. In Experiment 3, lactic acid and CFA decreased reinforcement rate without affecting fentanyl choice. Results extend the range of conditions across which pain-related manipulations fail to increase opioid seeking in rats and suggest that enhanced opioid-addiction risk in humans with chronic pain involves factors other than enhanced opioid reinforcement and relapse.
Identifiants
pubmed: 33765177
doi: 10.1007/s00213-021-05816-9
pii: 10.1007/s00213-021-05816-9
pmc: PMC10041878
mid: NIHMS1881147
doi:
Substances chimiques
Analgesics, Opioid
0
Fentanyl
UF599785JZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1885-1897Subventions
Organisme : NIGMS NIH HHS
ID : 1FI2GM128603
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA033934
Pays : United States
Organisme : NIDA NIH HHS
ID : P30DA0333034
Pays : United States
Organisme : NIDA NIH HHS
ID : F32DA047026
Pays : United States
Organisme : NIDA NIH HHS
ID : Funds of Intramural Research Program
Pays : United States
Références
Subst Abus. 2012;33(4):361-5
pubmed: 22989279
Pain. 2001 Mar;91(1-2):33-45
pubmed: 11240076
Pain Physician. 2017 Feb;20(2S):S93-S109
pubmed: 28226333
J Neurosci. 2015 Sep 02;35(35):12217-31
pubmed: 26338332
Pharmacol Biochem Behav. 1988 Oct;31(2):445-51
pubmed: 3244721
Drug Alcohol Depend. 2020 Apr 1;209:107902
pubmed: 32088587
PLoS One. 2016 Feb 25;11(2):e0150164
pubmed: 26915030
Clin J Pain. 2009 Mar-Apr;25(3):193-8
pubmed: 19333168
J Pain. 2002 Aug;3(4):309-19
pubmed: 14622755
Drug Alcohol Depend. 2019 Nov 1;204:107501
pubmed: 31479865
Neuropsychopharmacology. 2016 Jan;41(1):335-56
pubmed: 25976297
JAMA. 2003 May 14;289(18):2370-8
pubmed: 12746360
Mol Pain. 2014 Sep 23;10:62
pubmed: 25245060
Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
pubmed: 12402102
Psychopharmacology (Berl). 2020 Jul;237(7):2201-2212
pubmed: 32382785
Neuropsychopharmacology. 1996 Jun;14(6):375-424
pubmed: 8726752
J Pharmacol Exp Ther. 2015 Feb;352(2):208-17
pubmed: 25406170
J Pain. 2005 Dec;6(12):798-808
pubmed: 16326368
Neuropsychopharmacology. 2019 Nov;44(12):2022-2029
pubmed: 30818323
J Med Toxicol. 2012 Dec;8(4):393-9
pubmed: 23073725
Neuropharmacology. 2021 Mar 15;186:108476
pubmed: 33524407
Drug Alcohol Depend. 1980 Sep;6(3):163-73
pubmed: 6107237
Life Sci. 1989;45(23):2217-24
pubmed: 2601574
J Subst Abuse Treat. 2017 Jun;77:26-30
pubmed: 28476267
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3233-43
pubmed: 18640922
PLoS One. 2013 Nov 15;8(11):e79239
pubmed: 24260176
Neurology. 2007 Apr 10;68(15):1178-82
pubmed: 17420400
Neurosci Lett. 2016 Oct 6;632:44-9
pubmed: 27544012
Behav Brain Res. 2006 Jun 30;170(2):308-15
pubmed: 16675039
Front Pharmacol. 2021 Jan 29;11:615782
pubmed: 33584295
Nat Rev Neurosci. 2020 Nov;21(11):625-643
pubmed: 33024318
Pharmacol Biochem Behav. 2011 Mar;98(1):35-42
pubmed: 21147151
Nat Methods. 2010 Jun;7(6):447-9
pubmed: 20453868
Pain Res Manag. 2011 May-Jun;16(3):169-77
pubmed: 21766066
ACS Chem Neurosci. 2020 May 6;11(9):1300-1310
pubmed: 32271538
Brain Res Brain Res Rev. 2000 Aug;33(1):13-33
pubmed: 10967352
Neuropharmacology. 2019 Dec 1;160:107689
pubmed: 31271771
Pain. 1996 Sep;67(1):179-188
pubmed: 8895246
Prog Brain Res. 2010;186:141-57
pubmed: 21094890
Eur J Pain. 2012 Apr;16(4):485-95
pubmed: 22396078
Adv Pharmacol Sci. 2012;2012:281768
pubmed: 23243420
Pain Physician. 2017 Feb;20(2S):S111-S133
pubmed: 28226334
J Subst Abuse Treat. 2014 Aug;47(2):140-5
pubmed: 24814051
Psychopharmacology (Berl). 2018 May;235(5):1609-1618
pubmed: 29572653
Psychopharmacology (Berl). 1980;70(2):213-7
pubmed: 6776582
Nature. 1983 Mar 17-23;302(5905):251-3
pubmed: 6188055
J Pharmacol Exp Ther. 2012 Nov;343(2):389-400
pubmed: 22892341
Behav Neurosci. 2002 Feb;116(1):169-73
pubmed: 11895178
Neuropsychopharmacology. 2019 Sep;44(10):1681-1689
pubmed: 31043682
Lab Anim (NY). 2013 Aug;42(8):292-300
pubmed: 23877610
Neuropsychopharmacology. 2015 Jan;40(2):421-8
pubmed: 25060491
Neuropharmacology. 2019 May 15;150:200-209
pubmed: 30660628
Behav Pharmacol. 2021 Apr 1;32(2&3):142-152
pubmed: 33079736
Trends Pharmacol Sci. 2017 Feb;38(2):181-194
pubmed: 27916279
J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S80-6
pubmed: 20307799
Life Sci. 1982 Jul 5;31(1):67-75
pubmed: 7109855
Pharmacol Rev. 2019 Apr;71(2):225-266
pubmed: 30898855
Sci Signal. 2016 Nov 29;9(456):ra117
pubmed: 27899527
Prog Neurobiol. 2011 Mar;93(3):385-404
pubmed: 21216272
Pain. 2008 Sep 30;139(1):127-135
pubmed: 18455314
Pain. 2009 Jul;144(1-2):170-7
pubmed: 19435650
Psychopharmacology (Berl). 2020 Nov;237(11):3369-3381
pubmed: 32990768
Anesthesiology. 2007 Feb;106(2):312-22
pubmed: 17264726
Pain. 1992 Apr;49(1):129-135
pubmed: 1594274
J Pharmacol Exp Ther. 1977 Sep;202(3):660-9
pubmed: 19619
J Pain. 2012 Feb;13(2):146-54
pubmed: 22245713
Exp Clin Psychopharmacol. 2008 Oct;16(5):357-66
pubmed: 18837632
Pain. 2006 Sep;124(1-2):34-49
pubmed: 16650579
MMWR Morb Mortal Wkly Rep. 2018 Sep 14;67(36):1001-1006
pubmed: 30212442
Mol Pain. 2011 Jul 29;7:55
pubmed: 21801409
Trends Pharmacol Sci. 2018 Nov;39(11):911-916
pubmed: 30343726
Exp Clin Psychopharmacol. 2015 Oct;23(5):405-14
pubmed: 26375515
Anesthesiology. 2004 Jul;101(1):191-203
pubmed: 15220791